Curcumin inhibits trinitrobenzene sulphonic acid-induced colitis in rats by activation of peroxisome proliferator-activated receptor gamma

International Immunopharmacology

Volumn 6, Issue 8, 2006, Pages 1233-1242

  Zhang, Ming ^a   Deng, Changsheng ^a   Zheng, Jiaju ^b   Xia, Jian ^a   Sheng, Dan ^a  

^a WUHAN UNIVERSITY   (China)

^b Digestive Disease and Nutrition Research Center of Suzhou   (China)

Author keywords

Colitis; Curcumin; Cyclooxygenase 2; Peroxisome proliferator activated receptor gamma; Prostaglandin

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; CURCUMIN; CYCLOOXYGENASE 2; DEXAMETHASONE; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA 2; PROSTAGLANDIN E2; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS; COLON; CURCUMIN; CYCLOOXYGENASE 2; CYTOKINES; DEXAMETHASONE; DINOPROSTONE; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; PPAR GAMMA; PROSTAGLANDIN D2; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS; TIME FACTORS; TRINITROBENZENESULFONIC ACID; WEIGHT LOSS;

EID: 33744966571     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2006.02.013     Document Type: Article

References (52)

1. Ammon H.P.T., and Wahl M.A. Pharmacology of Curcuma longa. Planta Med 57 (1991) 1-7
2. Chainani-Wu N. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med 9 (2003) 161-168
3. Barclay L.R., Vinqvist M.R., Mukai K., Goto H., Hashimoto Y., Tokunaga A., et al. On the antioxidant mechanism of curcumin: classical methods are needed to determine antioxidant mechanism and activity. Org Lett 2 (2000) 2841-2843
4. Jobin C., Bradham C.A., Russo M.P., Juma B., Narula A.S., Brenner D.A., et al. Curcumin blocks cytokine-mediated NF-(B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 163 (1999) 3474-3483
5. Kuroda M., Mimaki Y., Nishiyama T., Mae T., Kishida H., Tsukagawa M., et al. Hypoglycemic effects of turmeric (Curcuma longa L. Rhizomes) on genetically diabetic KK-Ay mice. Biol Pharm Bull 28 (2005) 937-939
6. Xu J., Fu Y., and Chen A.P. Activation of peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of curcumin on rat hepatic stellate cell growth. Am J Physiol Gastrointest Liver Physiol 285 (2003) G20-G30
7. Chen A.P., and Xu J. Activation of PPAR{gamma} by curcumin inhibits Moser cell growth and mediates suppression of gene expression of cyclin D1 and EGFR. Am J Physiol Gastrointest Liver Physiol 288 (2005) G447-G456
8. Kang G., Kong P.J., Yuh Y.J., Lim S.Y., Yim S.V., Chun W., et al. Curcumin suppresses lipopolysaccharide-induced cyclooxygenase-2 expression by inhibiting activator protein 1 and nuclear factor kappa B bindings in BV2 microglial cells. J Pharmacol Sci 94 (2004) 325-328
9. Huang M.T., Lysz T., Ferraro T., Abidi T.F., Laskin J.D., and Conney A.H. Inhibitory effects of curcumin on in vitro lipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 51 (1991) 813-819
10. Brun R.P., Tontonoz P., Forman B.M., Ellis R., Chen J., Evans R.M., et al. Differential activation of adipogenes is by multiple PPAR isoforms. Genes Dev 10 (1996) 974-984
11. Bishop-Bailey D., and Wray J. Peroxisome proliferator-activated receptors: a critical review on endogenous pathways for ligand generation. Prostaglandins Other Lipid Mediat 71 (2003) 1-22
12. Su C.G., Wen X., Bailey S.T., Jiang W., Rangwala S.M., Keilbaugh S.A., et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 104 (1999) 383-389
13. Nakajima A., Wada K., Miki H., Kubota N., Nakajima N., Terauchi Y., et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 120 (2001) 460-469
14. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. 15-Deoxy-D12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83 (1995) 803-812
15. Marx N., Sukhova G., Murphy C., Libby P., and Plutzky J. Macrophages in human atheroma contain PPAR-γ-differentiation-dependent peroxisomal proliferator-activated receptor-γ (PPAR-γ) expression and reduction of MMP-9 activity through PPAR-gamma activation in mononuclear phagocytes in vitro. Am J Pathol 153 (1998) 17-23
16. Straus D.S., and Glass C.K. Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. Med Res Rev 21 (2001) 185-210
17. Straus D.S., and Glass C.K. Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol 51 (2005) 127-145
18. Salh B., Assi K., Templeman V., Parhar K., Owen D., Gomez-Munoz A., et al. Curcumin attenuates DNB-induced murine colitis. Am J Physiol Gastrointest Liver Physiol 285 (2003) G235-G243
19. Sugimoto K., Hanai H., Tozawa K., Aoshi T., Uchijima M., Nagata T., et al. Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice. Gastroenterology 123 (2002) 1912-1922
20. Jian Y.T., Mai G.F., Wang J.D., Zhang Y.L., Luo R.C., and Fang Y.X. Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol 11 (2005) 1747-1752
21. Ukil A., Maity S., Karmakar S., Datta N., Vedasiromoni J.R., and Das P.K. Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol 139 (2003) 209-218
22. Lytle C., Tod T.J., Vo K.T., Lee J.W., Atkinson R.D., and Straus D.S. The peroxisome proliferator-activated receptor gamma ligand rosiglitazone delays the onset of inflammatory bowel disease in mice with interleukin 10 deficiency. Inflamm Bowel Dis 11 (2005) 231-243
23. Sanchez-Hidalgo M., Martin A.R., Villegas I., and Alarcon De La Lastra C. Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 69 (2005) 1733-1744
24. Saubermann L.J., Nakajima A., Wada K., Zhao S., Terauchi Y., Kadowaki T., et al. Peroxisome proliferator-activated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis 8 (2002) 330-339
25. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., and Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96 (1989) 795-803
26. Rogler G., and Andus T. Cytokines in inflammatory bowel disease. World J Surg 22 (1998) 382-389
27. Dubuquoy L., Jansson E.A., Deeb S., Rakotobe S., Karoui M., Colombel J.F., et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124 (2003) 1265-1276
28. Hafraoui S., Lefebvre A.M., Geboes K., Cortot A., Auwerx J., Colombel J.F., et al. Ulcerative colitis is associated with a mucosal deficit in PPARgamma. Gastroenterology 116 suppl (2001) A689 [abstr]
29. Bassaganya-Riera J., Reynolds K., Martino-Catt S., Cui Y., Hennighausen L., Gonzalez F., et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology 127 (2004) 777-791
30. Katayama K., Wada K., Nakajima A., Mizuguchi H., Hayakawa T., Nakagawa S., et al. A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 124 (2003) 1315-1324
31. Cuzzocrea S., Ianaro A., Wayman N.S., Mazzon E., Pisano B., Dugo L., et al. The cyclopentenone prostaglandin 15-deoxy-delta (12,14)-PGJ2 attenuates the development of colon injury caused by dinitrobenzene sulphonic acid in the rat. Br J Pharmacol 138 (2003) 678-688
32. Zheng S., and Chen A. Activation of PPARgamma is required for curcumin to induce apoptosis and to inhibit the expression of extracellular matrix genes in hepatic stellate cells in vitro. Biochem J 384 (2004) 149-157
33. Wang Q., Herrera-Ruiz D., Mathis A.S., Cook T.J., Bhardwaj R.K., and Knipp G.T. Expression of PPAR, RXR isoforms and fatty acid transporting proteins in the rat and human gastrointestinal tracts. J Pharm Sci 94 (2005) 363-372
34. Lefebvre M., Paulweber B., Fajas L., Woods J., McCrary C., Colombel J.F., et al. Peroxisome proliferator-activated receptor gamma is induced during differentiation of colon epithelium cells. J Endocrinol 162 (1999) 331-340
35. Mansen A., Guardiola-Diaz H., Rafter J., Branting C., and Gustafsson J.A. Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 222 (1996) 844-851
36. Giri S., Rattan R., Singh A.K., and Singh I. The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma. J Immunol 173 (2004) 5196-5208
37. Singer I.I., Kawka D.W., Schloemann S., Tessner T., Riehl T., and Stenson W.F. Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115 (1998) 297-6
38. Murakami A., Hayashi R., Tanaka T., Kwon K.H., Ohigashi H., and Safitri R. Suppression of dextran sodium sulfate-induced colitis in mice by zerumbone, a subtropical ginger sesquiterpene, and nimesulide: separately and in combination. Biochem Pharmacol 66 (2003) 1253-1261
39. Radaelli F., Feltri M., Meucci G., Spinzi G., Terruzzi V., and Minoli G. Ischemic colitis associated with rofecoxib. Dig Liver Dis 37 (2005) 372-376
40. Singh V.P., Patil C.S., Jain N.K., and Kulkarni S.K. Aggravation of inflammatory bowel disease by cyclooxygenase-2 inhibitors in rats. Pharmacology 72 (2004) 77-84
41. Biancone L., Tosti C., De Nigris F., Fantini M., and Pallone F. Selective cyclooxygenase-2 inhibitors and relapse of inflammatory bowel disease. Gastroenterology 125 (2003) 637-638
42. Mahadevan U., Loftus Jr. E.V., Tremaine W.J., and Sandborn W.J. Safety of selective cyclooxygenase-2 inhibitors in inflammatory bowel disease. Am J Gastroenterol 97 (2002) 910-914
43. Kankuri E., Vaali K., Korpela R., Paakkari I., Vapaatalo H., and Moilanen E. Effects of a COX-2 preferential agent nimesulide on TNBS-induced acute inflammation in the gut. Inflammation 25 (2001) 301-310
44. Karmeli F., Cohen P., and Rachmilewitz D. Cycloxygenase-2 inhibitors ameliorate the severity of experimental colitis in rats. Eur J Gastroenterol Hepatol 12 (2000) 223-231
45. Martin A.R., Villegas I., and Alarcon de la Lastra C. The COX-2 inhibitor, rofecoxib, ameliorates dextran sulphate sodium induced colitis in mice. Inflamm Res 54 (2005) 145-151
46. Harris S.G., Padilla J., Koumas L., Ray D., and Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol 23 (2002) 144-150
47. Zamuner S.R., Warrier N., Buret A.G., MacNaughton W.K., and Wallace J.L. Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut 52 (2003) 1714-1720
48. Gilroy D.W., Colville-Nash P.R., Willis D., Chivers J., Paul-Clark M.J., and Willoughby D.A. Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5 (1999) 698-701
49. Subbaramaiah K., Lin D.T., Hart J.C., and Dannenberg A.J. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem 276 (2001) 12440-12448
50. Inoue H., Tanabe T., and Umesono K. Feedback control of cyclooxygenase-2 expression through PPARgamma. J Biol Chem 275 (2000) 28028-28032
51. Duvoix A., Blasius R., Delhalle S., Schnekenburger M., Morceau F., Henry E., et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223 (2005) 181-190
52. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 21 (2001) 2895-2900